Back
“AstraZeneca's heart drug Wainua flopped in a Phase 3 trial, failing to reduce cardiovascular deaths, crashing shares nearly 10% as a $15 billion-plus market opportunity evaporates overnight.”
Source
Matthew HerperX“AstraZeneca, Ionis report major trial failure wi…”span
“AstraZeneca, Ionis report major trial failure with heart disease drug”
Performance
Entry$172.86
Current$178.71
Since call-3.38%
Confidence72%
How this was scored
Judged byLLM · qwen/qwen3-coder-nextconfidence 100%
Horizon2026-07-09parsed as iso-date
ResolvedJul 10, 2026 · 12:29 UTC
The prediction and summary match the evidence, which confirms AstraZeneca and Ionis reported a major trial failure with the heart disease drug Wainua; the event occurred on 2026-07-09, before the deadline of 2026-07-09T23:59:59.000Z, and the share price drop and market impact were publicly reported.